Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Reviewing deaths in British and US hospitals: a study of two scales for assessing preventability.

Manaseki-Holland S, Lilford RJ, Bishop JRB, Girling AJ, Chen YF, Chilton PJ, Hofer TP; UK Case Note Review Group.

BMJ Qual Saf. 2017 May;26(5):408-416. doi: 10.1136/bmjqs-2015-004849. Epub 2016 Jun 22.

2.

Effect of early vs late tracheostomy placement on survival in patients receiving mechanical ventilation: the TracMan randomized trial.

Young D, Harrison DA, Cuthbertson BH, Rowan K; TracMan Collaborators.

JAMA. 2013 May 22;309(20):2121-9. doi: 10.1001/jama.2013.5154.

PMID:
23695482
3.

SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1.

Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K.

J Biol Chem. 2010 Mar 12;285(11):8340-51. doi: 10.1074/jbc.M109.088682. Epub 2010 Jan 8.

4.
5.

Case 7-2006: a man with altered mental status and acute renal failure.

Geoghegan J, Bleasdale JP, Bradberry SM.

N Engl J Med. 2006 Jun 22;354(25):2727-9; author reply 2727-9. No abstract available.

PMID:
16795152
6.

Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: identification of analogues with cellular activity.

Larsen SD, Stevens FC, Lindberg TJ, Bodnar PM, O'Sullivan TJ, Schostarez HJ, Palazuk BJ, Bleasdale JE.

Bioorg Med Chem Lett. 2003 Mar 10;13(5):971-5.

PMID:
12617932
8.

Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B.

Larsen SD, Barf T, Liljebris C, May PD, Ogg D, O'Sullivan TJ, Palazuk BJ, Schostarez HJ, Stevens FC, Bleasdale JE.

J Med Chem. 2002 Jan 31;45(3):598-622.

PMID:
11806712
9.

Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action.

Bleasdale JE, Ogg D, Palazuk BJ, Jacob CS, Swanson ML, Wang XY, Thompson DP, Conradi RA, Mathews WR, Laborde AL, Stuchly CW, Heijbel A, Bergdahl K, Bannow CA, Smith CW, Svensson C, Liljebris C, Schostarez HJ, May PD, Stevens FC, Larsen SD.

Biochemistry. 2001 May 15;40(19):5642-54.

PMID:
11341829
10.

Analysis of in vitro interactions of protein tyrosine phosphatase 1B with insulin receptors.

Wang XY, Bergdahl K, Heijbel A, Liljebris C, Bleasdale JE.

Mol Cell Endocrinol. 2001 Feb 28;173(1-2):109-20.

PMID:
11223182
11.

Unusual steroid specificity of the cell surface progesterone receptor on human sperm.

Blackmore PF, Fisher JF, Spilman CH, Bleasdale JE.

Mol Pharmacol. 1996 Apr;49(4):727-39.

PMID:
8609903
12.
14.

Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism.

Sizer KM, Smith CL, Jacob CS, Swanson ML, Bleasdale JE.

Mol Cell Endocrinol. 1994 Jul;103(1-2):1-12.

PMID:
7525381
15.

Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism.

Sizer KM, Smith CL, Jacob CS, Swanson ML, Bleasdale JE.

Mol Cell Endocrinol. 1994 Jun;102(1-2):119-29.

PMID:
7926264
16.
17.
18.
19.
20.

Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils.

Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, Smith RJ, Bunting S.

J Pharmacol Exp Ther. 1990 Nov;255(2):756-68.

PMID:
2147038

Supplemental Content

Loading ...
Support Center